ImmunOs appoints Steve Coats as chief development officer

6 December 2021
immunos_big

Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO).

Mr Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Prior to joining ImmunOs, Mr Coats served as CDO at Auregen Biotherapeutics, managing and leading R&D laboratories to develop innovative cell therapies and building a strong development pipeline.

From 2005 to 2020, he held several leading positions of increasing responsibility at AstraZeneca (LSE: AZN)_and MedImmune, most recently as vice president R&D, global project leader. From 1996 to 2005, he held various research positions of increasing responsibility at Amgen (Nasdaq: AMGN), where he focused on identifying the right targets and mechanistic areas in cancer for drug development of both small molecule and biologic-based therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology